Transparency notification BlackRock, Inc.

Brussels (Belgium), 8 July 2025 – 20:00 (CEST) – Regulated information

 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 4 July 2025. 

The notification was made following the acquisition or disposal of the control of an undertaking of the BlackRock group that holds a participating interest in UCB. 

On 1 July 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 10 848 463 UCB shares with voting rights and 118 231 assimilated financial instruments, representing together 5.64% of the total number of shares issued by the company (194 505 658), versus 5.07% (9 725 971UCB shares and 126 101 assimilated financial instruments) in the previous notification dated 11 March 2025.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 1 July 2025.
• Threshold crossed (in %): 5%.
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held: Please see the full chain of control in the ‘Chain of Control’ tab.
• Additional information: As a result of the acquisition of HPS Investment Partners, there has been a change to BlackRock’s group structure. Upon the close of the transaction, BlackRock, Inc. contributed all of its equity interests in BlackRock Finance, Inc. and Global Infrastructure Management, LLC to BlackRock Saturn Subco, LLC, a wholly owned subsidiary of the Company.

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations

Antje Witte 

T +32 2 559 94 14

antje.witte@ucb.com

Corporate Communications

Laurent Schots 

T+32 2 559 92 64

laurent.schots@ucb.com     

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).